anmelden
SLI
2.132,80
PKT
-4,19
PKT
-0,20
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 13.02.20 | Zurich Insurance Sector Perform | RBC Capital Markets | |
| 13.02.20 | Zurich Insurance buy | Goldman Sachs Group Inc. | |
| 12.02.20 | ABB (Asea Brown Boveri) buy | UBS AG | |
| 10.02.20 | Roche buy | Jefferies & Company Inc. | |
| 10.02.20 | ABB (Asea Brown Boveri) buy | Kepler Cheuvreux | |
| 10.02.20 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 10.02.20 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
| 07.02.20 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 07.02.20 | UBS Equal weight | Barclays Capital | |
| 07.02.20 | UBS Neutral | JP Morgan Chase & Co. | |
| 07.02.20 | Roche buy | UBS AG | |
| 06.02.20 | Roche overweight | JP Morgan Chase & Co. | |
| 06.02.20 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 06.02.20 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 06.02.20 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 05.02.20 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 05.02.20 | ABB (Asea Brown Boveri) buy | UBS AG | |
| 05.02.20 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 05.02.20 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 05.02.20 | UBS buy | Goldman Sachs Group Inc. | |
| 04.02.20 | Holcim overweight | JP Morgan Chase & Co. | |
| 04.02.20 | Roche buy | Deutsche Bank AG | |
| 04.02.20 | Givaudan buy | UBS AG | |
| 03.02.20 | Givaudan buy | UBS AG | |
| 03.02.20 | Roche overweight | JP Morgan Chase & Co. | |
| 03.02.20 | UBS overweight | JP Morgan Chase & Co. | |
| 03.02.20 | Zurich Insurance Hold | Deutsche Bank AG | |
| 31.01.20 | Roche Neutral | Credit Suisse Group | |
| 31.01.20 | Novartis Hold | Deutsche Bank AG | |
| 31.01.20 | Roche buy | Deutsche Bank AG | |
| 31.01.20 | Givaudan Underperform | Bernstein Research | |
| 30.01.20 | Novartis Neutral | Credit Suisse Group | |
| 30.01.20 | Roche overweight | Barclays Capital | |
| 30.01.20 | Roche buy | UBS AG | |
| 30.01.20 | Roche buy | Goldman Sachs Group Inc. | |
| 30.01.20 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 30.01.20 | Roche overweight | JP Morgan Chase & Co. | |
| 30.01.20 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 29.01.20 | UBS Underweight | Barclays Capital | |
| 29.01.20 | Novartis Underweight | JP Morgan Chase & Co. |